Skyrizi

Chemical Namerisankizumab-rzaa
Dosage FormInjection (subcutaneous; 75 mg/0.83 mL)
Drug ClassMonoclonal antibodies
SystemSkin
CompanyAbbVie Inc.
Approval Year2019

Indication

  • Skyrizi is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Last updated on 2/5/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.2019Journal of the American Academy of Dermatology